Comparative effectiveness of weekly versus every-2-weeks cetuximab in metastatic colorectal cancer in a US-insured population.
Francois-Xavier LamyMichael BatechEmmanuelle BoutmyPhilippe RongaShaista SalimChris P PescottPublished in: Journal of comparative effectiveness research (2020)
Aim: To test the noninferiority of cetuximab administered every 2 weeks (Q2W) versus once weekly (Q1W) in treating metastatic colorectal cancer (mCRC) with regard to overall survival (OS). Patients: Patients receiving cetuximab plus chemotherapy for mCRC in a line-agnostic setting. Methods: This cohort study in IBM MarketScan followed patients from initiation of cetuximab for mCRC until the end of the data availability period, proxy-based death or loss of insurance coverage for >30 days. Results: The hazard ratio for OS was 0.94 (0.85-1.03), and the inferiority hypothesis was rejected at p < 0.001. No significant differences were noted in rates of safety events between Q2W and Q1W. Conclusion: Our real-world study confirmed the noninferiority of cetuximab administered Q2W versus Q1W for OS.
Keyphrases
- metastatic colorectal cancer
- end stage renal disease
- chronic kidney disease
- ejection fraction
- locally advanced
- newly diagnosed
- peritoneal dialysis
- squamous cell carcinoma
- wild type
- machine learning
- electronic health record
- patient reported outcomes
- radiation therapy
- artificial intelligence
- preterm birth
- deep learning
- chemotherapy induced